Freyr Battery: Neuer Name, neues Geschäftsmodel - alte Probleme? | Freyr Battery: Neuer Name, neues Geschäftsmodel - alte Probleme ► Artikel lesen |
FREYR Battery Rebrands as T1 Energy | AUSTIN, Texas & NEW YORK--(BUSINESS WIRE)--FREYR Battery (NYSE: FREY) (or the "Company") is unveiling a strategic rebranding of the Company as T1 Energy Inc. ("T1"). This comprehensive rebrand includes... ► Artikel lesen |
Freyr Battery to acquire Trina Solar U.S. manufacturing assets | The battery maker reports that acquiring the module manufacturing assets is the first step in its plan to build out a vertically integrated domestic manufacturing footprint that will next include a... ► Artikel lesen |
NIU Group Acquires Chile's Minera Tres Valles, Initiating a New Phase of Operations at the Copper Mine | Austrian investor Cevdet Caner, through NIU Group, has announced the acquisition and strategic renewal of Chilean mining company Minera Tres Valles (MTV). This marks the beginning of a new chapter... ► Artikel lesen |
Niu Technologies Q1 Sales Volume Climbs With Strong China Sales | BEIJING (dpa-AFX) - Niu Technologies (NIU), a Chinese provider of smart urban mobility solutions, reported Friday higher sales volume in its first quarter, with significant growth in domestic... ► Artikel lesen |
Niu Technologies Provides First Quarter 2025 Sales Volume Update | BEIJING, April 04, 2025 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU", or "the Company") (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume... ► Artikel lesen |
Sangamo-Aktie schießt hoch: Deal mit Eli Lilly - die Details | Mit einem Plus von gut 20 Prozent gehört die Aktie der Biotech-Gesellschaft Sangamo Therapeutics am Freitag zu den wenigen Aktien an der Börse, die mit einem sehr deutlichen Kursaufschlag gehandelt... ► Artikel lesen |
Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System | Agreement grants Lilly rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and... ► Artikel lesen |
Sangamo Therapeutics Aktie: Auf unsicheren Füßen? | Biotechnologieunternehmen kämpft mit Kurseinbruch nach Partnerschaftsende, zeigt jedoch Fortschritte bei Fabry-Therapie und neuen Kooperationen mit Genentech und Astellas. Sangamo Therapeutics verzeichnet... ► Artikel lesen |